Role of thrombin as a tumor growth factor

Cell Cycle

Volumn 9, Issue 4, 2010, Pages 656-661

  Green, David ^a   Karpatkin, Simon ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cell cycle; MiR 222; PAR 1; Skp2; Thrombin; TRAMP mice; Tumor

Indexed keywords

CANCER GROWTH FACTOR; CYCLIN A; CYCLIN D; FIBRINOGEN; HIRUDIN; MICRORNA; PROTEIN P27; PROTEINASE ACTIVATED RECEPTOR; S PHASE KINASE ASSOCIATED PROTEIN 2; THROMBIN; THROMBIN RECEPTOR; WARFARIN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; DEATH RECEPTOR 3; MIRN222 MICRORNA, MOUSE; OLIGOPEPTIDE; S PHASE KINASE ASSOCIATED PROTEIN; SIGNAL PEPTIDE; THREONYL PHENYLALANYL LEUCYL LEUCYL ARGINYL ASPARAGINE; THREONYL-PHENYLALANYL-LEUCYL-LEUCYL-ARGINYL-ASPARAGINE; TNFRSF25 PROTEIN, MOUSE;

ANGIOGENESIS; ANTICOAGULATION; BREAST CALCIFICATION; BREAST TUMOR; C57BL 6 MOUSE; CANCER CELL; CANCER INHIBITION; CANCER PATIENT; CANCER SURVIVAL; CANCER TRANSPLANTATION; CELL ACTIVATION; CELL CYCLE; CELL GROWTH; CELL STRAIN LNCAP; CLINICAL OBSERVATION; DORMANCY; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INDUCTION; FIBROBLAST; HUMAN; MELANOMA; METASTASIS; MITOGENICITY; NONHUMAN; PROGNOSIS; PROSTATE CANCER; PROTEIN FUNCTION; REVIEW; SMOOTH MUSCLE FIBER; THROMBOCYTE ADHESION; THROMBOSIS; THYROID CANCER; TRANSGENIC MOUSE; TUMOR BIOPSY; TUMOR CELL LINE; TUMOR GROWTH; UPREGULATION; ANIMAL; ANTICOAGULANT THERAPY; ARTICLE; C57BL MOUSE; CELL LINE; GENETICS; MALE; METABOLISM; MOUSE; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR;

ANIMALIA; MUS;

ANIMALS; CELL LINE; CYCLIN A; CYCLIN D; CYCLIN-DEPENDENT KINASE INHIBITOR P27; HIRUDIN THERAPY; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MICRORNAS; OLIGOPEPTIDES; PROSTATIC NEOPLASMS; RECEPTORS, THROMBIN; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 25; S-PHASE KINASE-ASSOCIATED PROTEINS; THROMBIN;

EID: 77953149887     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.9.4.10729     Document Type: Review

References (49)

1. Kip1, in association with the upregulation of Skp2 and MiR-222. Cancer Res 2009; 69:3374-81.
2. Trousseau A. Plegmasie alba dolens. Clinique Medical de Hotel-Dieu de Paris, London. New Syndenham Society 1865; 3:94.
3. Prins M, Otten H-MM. Thrombosis and Cancer: A short history of Trousseau's syndrome. In: Lugassy G, Falanga A, Kakkar A, Rickles F, eds. Thrombosis and Cancer. London, NY: Taylor and Francis 2004; 1-10.
4. Nierodzik M, Plotkin A, Kajumo F, Karpatkin S. Thrombin stimulates tumor-platelet adhesion in vitro and metastasis in vivo. J Clin Invest 1991; 87:229-36.
5. Nierodzik ML, Bain RM, Liu L-X, Shivji M, Takeshita K, Karpatkin S. Presence of the seven transmembrane thrombin receptor on human tumour cells: effect of activation on tumour adhesion to platelets and tumour tyrosine phosphorylation. Brit J Haematol 1996; 92:452-7.
6. Nierodzik M, Kajumo F, Karpatkin S. Effect of thrombin treatment of tumor cells on adhesion of tumor cells to platelets in vitro and metastasis in vivo. Cancer Res 1992; 52:3267-72.
7. Klepfish A, Greco MA, Karpatkin S. Thrombin stimulates melanoma tumor-cell binding to endothelial cells and subendothelial matrix. Int J Cancer 1993; 53:978-82.
8. Wojtukiewicz M, Tang D, Nelson K, Walz D, Diglio C, Honn K. Thrombin enhances tumor cell adhesive and metastatic properties via increased allbbβ3 expression on the cell surface. Thromb Res 1992; 68:223-45.
9. Wojtukiewicz M, Tang D, Ben-Josef E, Renaud C, Walz D, Honn K. Solid tumor cells express functional tethered ligand thrombin receptor. Cancer Res 1995; 55:698-7004.
10. Nierodzik M, Chen K, Takeshita K, Li J, Huang Y, Feng X, et al. Protease-activated receptor 1 (PAR-1) is required and rate-limiting for thrombin-enhanced experimental pulmonary metastasis. Blood 1998; 92:3694-700.
11. Even-Ram S, Uziely B, Cohen P, Grisaru-Granovsky S, Maoz M, Ginzburg Y, et al. Thrombin receptor overexpression in malignant and physiological invasion processes. Nature Medicine 1998; 4:909-14.
12. Zain J, Huang Y-Q, Feng X-S, Nierodzik ML, Li J-J, Karpatkin S. Concentration dependent dual effect of thrombin on impaired growth/apoptosis or mitogenesis in tumor cells. Blood 2000; 95:1993-9.
13. Carney D, Glenn K, Cunningham D. Conditions which affect initiation of animal cell division by trypsin and thrombin. J Cell Physiol 1978; 95:13-22.
14. Carney D, Stiernberg J, Fenton J. Initiation of proliferative events by human α-thrombin requires both receptor binding and enzymatic activity. J Cell Biochem 1984; 26:181-95.
15. Chen L, Buchanan J. Mitogenic activity of blood components I. Thrombin and prothrombin. Proc Natl Acad Sci USA 1975; 72:131-5.
16. Glenn K, Carney D, Fenton J, Cunningham D. Thrombin active site regions required for fibroblast receptor binding and initiation of cell division. J Biol Chem 1980; 255:6609-16.
17. Gospodarowicz D, Brown K, Birdwell C, Zetter B. Control of proliferation of human vascular endothelial cells. Characterization of the response of human umbilical vein endothelial cells to fibroblast growth factor, epidermal growth factor and thrombin. J Cell Biol 1978; 77:774-88.
18. Morris D, Ward J, Carney D. Thrombin promotes cell transformation in Balb 3T3/A 31-1-13 cells. Carcinogenesis 1992; 13:67-73.
19. Nierodzik ML, Karpatkin S. Thrombin induces tumor growth, metastasis and angiogenesis: Evidence for a thrombin-regulated dormant tumor phenotype. Cancer Cell 2006; 10:355-62.
20. Caunt M, Hu L, Tang T, Brooks PC, Ibrahim S, Karpatkin S. Growth-regulated oncogene is pivotal in thrombin-induced angiogenesis. Cancer Res 2006; 66:4125-32.
21. Hu L, Roth JM, Brooks P, Ibrahim S, Karpatkin S. Twist is required for thrombin-induced tumor angiogenesis and growth. Cancer Res 2008; 68:4296-302.
22. Hu L, Roth JM, Brooks P, Luty J, Karpatkin S. Thrombin UpRegulates Cathepsin-D which Enchances Angiogenesis, Growth and Metastasis. Cancer Res 2008; 68:1-8.
23. Hu L, Lee M, Campbell W, Perez-Soler R, Karpatkin S. Role of Endogenous Thrombin in tumor implantation, seeding and spontaneous metastasis. Blood 2004; 104:2748-51.
24. Bastida E, Ordinas A, Escolar G, Jamieson G. Tissue factor in microvesicles shed from U87 MG human glioblastoma cells induces coagulation, platelet aggregation and thrombogenesis. Blood 1984; 64:177-84.
25. Curatolo L, Colucci M, Cambini A, Poggi A, Morasca L, Donati M, et al. Evidence that cells from experimental tumors can activate coagulation factor X. Brit J Haematol 1979; 40:228-33.
26. Dvorak H, Van deWater L, Bitzer A, Dvorak A, Anderson D, Harvey V, et al. Procoagulant activity associated with plasma membrane vesicles shed by cultured tumor cells. Cancer Res 1983; 43:4334-42.
27. Gordon S, Cross B. A factor X-activating cysteine protease from malignant tissue. J Clin Invest 1981; 67:1665-71.
28. Honn K, Sloane B, Cavanaugh P. Role of the coagulation system in tumor-cell-induced platelet aggregation and metastasis. Haemostasis 1988; 18:37-46.
29. Kadish J, Wenc K, Dvorak H. Tissue factor activity of normal and neoplastic cells: quantitation and species specificity. J Natl Cancer Inst 1983; 70:551-7.
30. Pearlstein E, Ambrogio C, Gasic G, Karpatkin S. Inhibition of platelet aggregating activity of two human adenocarcinomas of the colon and an anaplastic murine tumor with a specific thrombin inhibitor: dansylarginine N-(3-ethyl-1,5-pentanediyl)amide. Cancer Res 1981; 41:4535-9.
31. Yoda Y, Abe T. Fibrinopeptide A (FPA) level and fibrinogen kinetics in patients with malignant disease. Thromb Haemostasis 1981; 46:706-9.
32. Merskey C, Johnson A, Harris J, Want M, Swain S. Isolation of fibrinogen-fibrin related antigen from human plasma by immune-affinity chromatography: its characterization in normal subjects and in defibrinating patients with abruptio placentae and disseminated cancer. Brit J Haematol 1980; 44:655-70.
33. Peuscher F, Cleton F, Armstrong L, Stoepman van Dalen E, van Aken W. Significance of plasma fibrinopeptide A (FPA) in patients with malignancy. J Lab Clin Med 1980; 96:5-14.
34. Rickles F, Edwards R. Activation of blood coagulation in cancer: Trousseau's syndrome revisited. Blood 1983; 62:14-31.
35. Fisher E, Ruf W, Mueller B. Tissue factor-initiated thrombin generation activates the signaling thrombin receptor on malignant melanoma cells. Cancer Res 1995; 55:1629-32.
36. Mueller B, Reisfeld R, Edgington T, Ruf W. Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis. Proc Natl Acad Sci USA 1992; 89:832-6.
37. Bromberg M, Konigsberg W, Madison J, Pacoashe A, Garen A. Tissue factor promotes melanoma metastasis by a pathway independent of blood coagulation. Proc Natl Acad Sci USA 1995; 92:8205-9.
38. Contrino J, Haiar G, Kreutzer D, Rickles FR. In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. Nature Med 1996; 2:209-15.
39. Zacharski L, Memoli V, Morain W, Schlaeppi J-M, Rousseau S. Cellular localization of enzymaticallyactive thrombin in intact tissue by hirudin binding. Thromb Haemostas 1995; 73:793-7.
40. MacKie RM, Reid R, Junor B. Fatal melanoma transferred in a donated kidney 16 years after melanoma surgery. N Engl J Med 2003; 348:567-8.
41. Harach HR, Franssila KO, Wasenius VM. Occult papillary carcinoma of the thyroid. A quot;normalquot; finding in Finland. A systematic autopsy study. Cancer 1985; 56:531-8.
42. Nielsen M, Thomsen JL, Primdahl S, Dyreborg U, Andersen JA. Breast cancer and atypia among young and middle-aged women: a study of 110 medicolegal autopsies. Br J Cancer 1987; 56:814-9.
43. Konety BR, Bird VY, Deorah S, Dahmoush L. Comparison of the incidence of latent prostate cancer detected at autopsy before and after the prostate specific antigen era. J Urol 2005; 174:1785-8.
44. Rawstron A, Yuille M, Fuller J, Cullen M, Kennedy B, Richards S, et al. Inherited predisposition to CLL is detectable as a subclinical monoclonal B-lymphocyte expansion. Blood 2002; 100:2289-90.
45. Kyle R. Monoclonal gammopathy of undetermined significance and solitary myeloma. Hematology/oncology clinics of North America 1997; 11:71.
46. Shulman S, Lindmarker P. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of anti-coagulation trial. NEJM 2000; 3432:1953.
47. Miller GJ, Bauer KA, Howarth DJ, Cooper JA, Humphries SE, Rosenberg RD. Increased incidence of neoplasia of the digestive tract in men with persistent activation of the coagulant pathway. J Thromb Haemost 2004; 2:2107-14.
48. Wu C, Alman BA. Side population cells in human cancers. Cancer Lett 2008; 268:1-9.
49. Hu L, Karpatkin S. (Personal Communication) 2009.